Q3 EPS Estimates for Vera Therapeutics Cut by HC Wainwright

Vera Therapeutics, Inc. (NASDAQ:VERA) – Equities researchers at HC Wainwright dropped their Q3 2026 earnings per share (EPS) estimates for Vera Therapeutics in a research report issued to clients and investors on Wednesday, July 8th. HC Wainwright analyst A. He now forecasts that the company will post earnings per share of ($1.71) for the quarter, down from their previous forecast of ($1.57). HC Wainwright currently has a “Buy” rating and a $125.00 target price on the stock. The consensus estimate for Vera Therapeutics’ current full-year earnings is ($6.23) per share. HC Wainwright also issued estimates for Vera Therapeutics’ Q4 2026 earnings at ($1.68) EPS, FY2026 earnings at ($6.79) EPS and FY2027 earnings at ($3.84) EPS.

Other analysts have also issued reports about the stock. Evercore set a $91.00 price target on shares of Vera Therapeutics in a research report on Friday, May 15th. Bank of America boosted their price objective on shares of Vera Therapeutics from $65.00 to $70.00 and gave the company a “buy” rating in a research report on Tuesday. William Blair reiterated an “outperform” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. The Goldman Sachs Group reissued a “buy” rating and set a $90.00 target price on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Finally, Guggenheim boosted their price target on shares of Vera Therapeutics from $56.00 to $76.00 and gave the company a “buy” rating in a report on Wednesday. Eleven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Vera Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $84.58.

Vera Therapeutics Trading Up 0.0%

Shares of NASDAQ VERA opened at $42.45 on Friday. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.15. Vera Therapeutics has a one year low of $19.07 and a one year high of $56.05. The business has a 50-day moving average price of $36.50 and a two-hundred day moving average price of $41.10. The firm has a market capitalization of $3.05 billion, a PE ratio of -7.66 and a beta of 0.92.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same quarter in the previous year, the business earned ($0.81) earnings per share.

Institutional Investors Weigh In On Vera Therapeutics

Large investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Vera Therapeutics by 7.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,905 shares of the company’s stock valued at $753,000 after purchasing an additional 2,210 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Vera Therapeutics by 22.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 98,013 shares of the company’s stock worth $2,354,000 after buying an additional 17,907 shares during the last quarter. Jane Street Group LLC lifted its stake in shares of Vera Therapeutics by 297.1% in the first quarter. Jane Street Group LLC now owns 41,578 shares of the company’s stock worth $999,000 after buying an additional 62,678 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Vera Therapeutics by 550.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 310,547 shares of the company’s stock worth $7,316,000 after buying an additional 262,805 shares during the period. Finally, Legal & General Group Plc boosted its holdings in shares of Vera Therapeutics by 1.7% during the 2nd quarter. Legal & General Group Plc now owns 50,418 shares of the company’s stock worth $1,188,000 after buying an additional 825 shares during the period. Institutional investors own 99.21% of the company’s stock.

Insider Buying and Selling at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 46,250 shares of the company’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the completion of the sale, the chief executive officer owned 151,994 shares in the company, valued at approximately $6,429,346.20. This represents a 23.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 106,201 shares of company stock valued at $4,348,762 over the last ninety days. 15.90% of the stock is owned by insiders.

Vera Therapeutics News Summary

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: The FDA granted accelerated approval to Trutakna, a significant commercialization milestone that strengthens Vera Therapeutics’ growth outlook and supports the stock. FDA grants accelerated approval to Vera Therapeutics’ Trutakna
• Positive Sentiment: HC Wainwright reiterated a Buy rating and raised its price target to $125, signaling confidence in Vera’s commercial opportunity despite trimming near-term earnings estimates. HC Wainwright price target update
• Positive Sentiment: Wedbush also lifted its price target to $43, showing that analysts remain constructive on the stock after the FDA news. Wedbush price target update
• Neutral Sentiment: Vera announced a planned regulatory leadership transition, appointing Nancy Boman as Chief Regulatory Officer while William Turner retires; this appears to be routine succession rather than a major business change. Vera Therapeutics leadership transition announcement
• Negative Sentiment: CEO Marshall Fordyce sold 46,250 shares under a pre-arranged 10b5-1 plan, which may slightly pressure sentiment even though the sale was scheduled in advance. SEC filing for CEO Marshall Fordyce stock sale
• Negative Sentiment: HC Wainwright cut its 2026, Q3 2026, Q4 2026, and FY2027 EPS estimates, highlighting that the company still faces near-term loss expectations despite the optimistic price target. Vera Therapeutics analyst estimate revisions

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.